Ares Capital Corporation (NASDAQ:ARCC)’s shares dropped 2.18% to $17.02. The company on July 16 said it has priced a public offering of 13,500,000 shares of its common stock. Ares Capital has granted the underwriters an option to purchase up to an additional 2,025,000 shares of common stock. The offering is subject to customary closing conditions and is expected to close on July 21, 2014. The offering of the shares is being made under Ares Capital’s shelf registration statement (as amended), which was filed with, and declared effective by, the Securities and Exchange Commission. On July 15, 2014, the official close price of Ares Capital’s common stock on The NASDAQ Global Select Market under the symbol “ARCC” was $17.40 per share.
SunEdison, Inc. (NYSE:SUNE)’s shares increased 0.39% to $23.44. The company on July 10 said a new project that will install 159 kilowatts (kW) of solar PV micro-grids with battery storage in six remote Indian villages, which will bring electricity to, and thereby improve health and education for, 4,875 off-grid people. Working with the Government of India’s Rural Electrification Corporation (REC) and the Madhya Pradesh Urja Vikas Nigam state agency, SunEdison will build, operate and then transfer the facilities to a public entity after five years, giving the freedom of renewable, reliable energy to those who need it the most.
Kodiak Oil & Gas Corp (USA) (NYSE:KOG)’s shares gained 5.50% to $15.73. Levi & Korsinsky on July 16 is investigating the Board of Directors of Kodiak Oil & Gas Corp. (“Kodiak” or “the Company”) (KOG) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Whiting Petroleum Corporation. Under the terms of the transaction, Kodiak shareholders will receive 0.177 of a share of Whiting stock for each share of Kodiak common stock they own, representing a value of $13.90 per share based on the closing price of Whiting common stock on July 11, 2014. The investigation concerns whether the Board of Kodiak breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Whiting Petroleum Corporation is underpaying for Kodiak shares. In particular, shares of Kodiak traded above the offer price the day before the merger was announced, and at least one analyst set a price target of $19.00 per share.
Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)
Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.
Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.
Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).
That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).
The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.
Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.
The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.
Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.
Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)
Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.
Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.
Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.
Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.
The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.
Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.
Bristol-Myers declined to comment.
Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.
The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.
Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.
On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.
Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.
The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.